Welcome EAC to Colorado January 12-13, 2023





an internet the second second second

University of Colorado Anschutz Medical Campus

Steven Dubinett, MD

Associate Vice Chancellor for Research, UCLA; Interim Dean, David Geffen SOM; Director of Clinical and Translational Sciences Institute; Chief, Pulmonary and Critical Care, UCLA (CTSA PI)



Alexander Krist, MD, MPH

Director of Community-Engaged Research at the Wright Center for Clinical and Translational Research, Associate Professor of family medicine and population health at Virginia Commonwealth University





Cynthia Morris, PhD, MPH

Sr. Associate Director and co-PI, Oregon Clinical and Translational Research Institute, Professor of Medical Informatics and Clinical Epidemiology, School of Medicine, OHSU



Tesheia Johnson, MBA, MHS

Deputy Director and Chief Operating Officer of Yale Center for Clinical Investigation and the Associate Director for Clinical Research for Yale School of Medicine





Dan Cooper, MD

Associate Vice Chancellor for Clinical and Translational Research at UC Irvine, Associate Director of UC Irvine's Institute for Clinical Translational Science, Professor of Pediatrics



Peter Embi, MD, MS

Chair and Senior Vice President for Research and Innovation, Department of Biomedical Informatics, Vanderbilt University Medical Center





Jareen Meinzen-Derr, PhD, MPH

PI – Center For Clinical and Translational Science & Training, Professor Dept. of Pediatrics, Co-Director, Faculty Diversity, Equity & Inclusion, Cincinnati Children's Hospital Medical Center, University of Cincinnati SOM (CTSA MPI)





NCATS Program Officer

Pablo Cure, MD

Division of Clinical Innovation, NCATS, formerly Program Officer / Health Scientist Administrator at National Heart, Lung, and Blood Institute





This Year's Format for EAC Meeting

- In person/virtual sessions Thursday pm, evening and Friday am.
- Tour of new CCTSI facility at AHSB Thurs. pm
- Overview & Plans for year 5 of this grant cycle, and next cycle
- Emphasis this year will be on plans for CCTSI 4.0 (2023-30)
- Reports from Leaders of Modules within new structure
- Closed EAC Session
- Feedback Session



Progress Report of Yr 5 Summary of Future Directions and Goals





Ronald J. Sokol, MD, FAASLD Director and P.I. of CCTSI Assistant Vice Chancellor of Clinical and Translational Science Chief Scientific Officer, Child Health University of Colorado – Anschutz Medical Campus



Colorado Clinical and Translational Sciences Institute (CCTSI)

Vice Chancellor of Research

Thomas Flaig, MD Professor of Medicine Oncology





Chief Research Informatics Officer

Melissa Haendel, PhD

Professor of Biomedical Informatics, Biochemistry and Molecular Genetics CD2H, N3C, Monarch, NCI Data Harmonization, RECOVER RWE





Associate Vice Chancellor for Regulatory Compliance

Alison Lakin, RN, LLB, LLM, PhD Office of the VCR





Chief Clinical Research Officer UC Health Associate Dean Clinical Research SOM

Thomas Campbell, MD

Professor of Medicine Infectious Disease





Chief Scientific Officer, Child Health Associate Dean for Child Health Research, SOM

Ronald Sokol, MD

Distinguished Professor of Pediatrics Pediatric GI, Hepatology, Nutrition





Director of Operations, MPI, CCTSI Vice Chair Research, Dept. of Medicine, SOM

Janine Higgins, PhD Professor of Medicine Admin-Research





CCTSI Vision



Accelerate and catalyze the translation of innovative science into improved, equitable health and patient care for all




CCTSI 3.0 Mission



- Catalyze and enhance scientific discovery, innovation, dissemination and translation across the lifespan
- Educate and sustain a resilient, innovative and diverse translational science workforce
- Promote and ensure an efficient, safe, collaborative and integrated research environment
- Engage stakeholders and communities across the entire translational spectrum



Spectrum of Translational Research







CCTSI 3.0 Overall Strategic Goals

Goal 1: Develop, educate and sustain a **diverse translational science workforce** to ensure highest research innovation, quality and safety

Goal 2: Create a translational research environment in which **team science and collaboration** both locally and nationally are facilitated, supported and valued

Goal 3: Engage local and national communities and stakeholders in all phases of the translational research process



CCTSI 3.0 Overall Strategic Goals

Goal 4: Create **novel methodologies and resources** to support and integrate research in **special populations**, including children, the elderly, the underserved and those with rare diseases.

Goal 5: Further innovate and **streamline our processes and enhance our informatics** capacity for research start-up, implementation and oversight to promote quality, efficiency, & safety of our research and our active participation in the national CTSA Trial Innovation Network.



CCTSI 3.0 Grants


NOGA (UL1, KL2, TL1) - 2018 Admin Supplement (OnCore Acceleration) 2018 Admin Supplement INCLUDE -Trisome project 2019 Admin Supplement KL2-INCLUDE 2020 Admin Supplement Participation in N3C 2020 Admin Supplement Prior Approval Process Professional 2020 KL2 Diversity Supplement 2021 Admin Supplement COVID mAb RWE project 2021



• Funding Period May 1, 2018 to April 30, 2023

UL1 total = \$40,466,652 TL1 total = \$2,783,180 KL2 total = \$4,551,5 **TOTAL = \$47,801,382 + 1,339,032 + 775,742 + 99,812, + 140,430 + 322,233 (+ 8,699,359) = \$50,478,631 (\$59,177,990)**





Colorado Clinical and Translational CCTSI Sciences Institute (CCTSI)

OF COLORADO DENVER | ANSCHUTZ MEDICAL CAMPUS

CCTSI Leadership Team

Director: Ronald Sokol, MDDirector of Operations: Janine Higgins, PhDDFA: Tim Lockie, MS, MBA

Associate Directors:

- Wendy Kohrt, PhD
- Lisa Cicutto, PhD, RN
- Tell Bennet MD, MS
- Alison Lakin RN, JD
- Donald Nease, MD, MPH
- Thomas Campbell, MD
- Adit Ginde, MD, MPH

















CCTSI Partnering Institutions

- Three Universities
 - CU Denver (CU-D)
 - CU-Anschutz Medical Campus: 6 health profession schools/colleges*
 - Downtown Denver
 - CU Boulder (CU-B)

Colorado State University (CSU)






• Six Affiliated Hospitals and Health Care Organizations** UCH (UCHealth), CHCO, DHH, NJH, RMVAMC, KP

* Only medical, pharmacy, dental and public health schools in Colorado **Each is a separate legal entity, <u>none</u> owned by Univ. of Colorado





CCTSI Community Partners

October 2021:

CU-Anschutz



(CT)

ions, Nursing

Native Programs, CHAR

CU Denver and CU Anschutz: Community E **Hispanic Serving Institution Designation** Under-Reso (US Dept. of Education) Native Ame partnership **New Center for Health Equity** • PACT Focu

 San Luis Va **High Plains**


• >20 Commun

state, includin

CE&R Reach in Colorado

PBRNs = SNOCAP CRL = Community Research Liaisons

People of Color




Colorado Clinical and Translational Sciences Institute (CCTSI)


G

CCTSI Members

CCTSI Monthly Membership Growth



CCTSI Membership by Academic Affiliation



 Missing or Not reported
 Colorado State University
 Kaiser Permanente of Colorado
 Other
 University of Colorado Anschutz Medical Campus
 University of Colorado Boulder
 University of Colorado Denver

CU Anschutz Campus




Anschutz Health Sciences Building





Colorado Clinical and Translational Sciences Institute (CCTSI)


Total Research Grants – CU Denver Millions



Colorado Clinical and Translational Sciences Institute (CCTSI)

راجا

Total <u>NIH</u> Grant Awards – CU Denver Millions






Grant Funding of CCTSI University Partners

University or School	Location	# Faculty	# Students	FY-22 NIH Funding (Total Cost)	FY-22 Total Funding
CU Anschutz	Aurora	5,499	4,571	\$326.4M	\$691.6M
Medicine	Aurora	4,913	1,716	\$284.1M	\$577.2M
Nursing	Aurora	186	1,244	\$1.7M	\$8.8M
Pharmacy	Aurora	111	564	\$7.9M	\$15.5M
Dentistry	Aurora	132	324	\$4.7M	\$4.4M
Public Health	Aurora	157	723	\$22.7M	\$52.7M
CU Denver	Denver	1,127	14,884	\$7.5M	\$18.9M
CU Boulder	Boulder	4,150	35,897	\$55.9M	\$630.1M
Colorado State	Ft. Collins	1,872	32,908	\$48.3M	\$391.7M
TOTAL		12,648	88,260	\$438.1M	\$1,732.3M

Colorado Clinical and Translational Sciences Institute (CCTSI)

CCTSI Annual Funding: 2018 - 2023




Colorado Clinical and Translational Sciences Institute (CCTSI)

G

CCTSI Annual Funding: 2018 – 2023

(includes supplements)



Colorado Clinical and Translational Sciences Institute (CCTSI)


G

CCTSI Operating Budget: FY 2023

CCTSI Programs		NIH CTSA Grants (Total Costs)		Chancellor & VCR Funds		UCH upport	SOM Support	SOM Addn'l Support for CCTSI Ops		CHCO Support		TOTAL		Percent Total
A. Administration Core:	\$	921,201	\$	425,045	\$	-		\$	83,597			\$	1,429,843	11%
B. Informatics	\$	771,662	\$	503,929	\$	-		\$	-			\$	1,275,591	10%
C. Community Engagement & Team Science	\$	790,680	\$	183,474	\$	-		\$	-			\$	974,154	8%
D. Translational Endeavors (ETCD-Pilots)	\$	1,843,215	\$	20,208	\$	-	\$500,000	\$	-	\$	200,000	\$	2,563,423	20%
E. Research Methods (RKS-BERD-Ethics)	\$	874,823	\$	116,209	\$	58,564		\$	111,480			\$	1,161,077	9%
F. Hub Research Capacity (CTRC + ISP)	\$	2,343,696	\$	180,649	\$1	,127,047		\$	-	\$	850,000	\$	4,501,392	35%
G. Network Capacity (TIN)	\$	267,111			\$	-		\$	-			\$	267,111	2%
H1. Innovation Ecosystem	\$	226,325	\$	9,470	\$	-		\$	-			\$	235,795	2%
H2. Early Life Exposures Program (ELEP)	\$	358,409			\$	-		\$	-			\$	358,409	3%
Total UL1 Program	\$	8,397,123	\$	1,438,984	\$1	,185,611	\$500,000	\$	195,077	\$´	1,050,000	\$	12,766,795	100%
Total KL2 Program(7 Scholars)	\$	775,990				-	-		_			\$	775,990	
Total TL1 Program (11 Trainees)	\$	638,951										\$	638,951	
Supplements: mAB RWE & KL2 Diversity	\$	2,881,669										\$	2,881,669	
Total CCTSI Program Budget	\$	12,693,733	\$	1,438,984	\$1	,185,611	\$500,000	\$	195,077	\$	1,050,000	\$ ⁻	17,063,405	

Colorado Clinical and Translational Sciences Institute (CCTSI)

CCTSI Response to Public Health Emergency





Colorado Clinical and Translational Sciences Institute (CCTSI)

CCTSI Response to COVID-19

- CTRCs outpatient visits for Therapeutic and Vaccine trials
- CTRCs inpatient visits and mobile nursing mAb infusions & other trials
- CReST study coordinators & regulatory teams reassigned
- Perinatal CTRC research nurses reassigned
- Core Lab SARS-CoV-2 testing for trials
- Logistical and scheduling support auxiliary facilities (trailers)
- Regulatory Support designated clinical study groups, reviewed all studies, suspended and restarted studies
- Accelerated IRB turn-around, contracting, clinical trial start-up (10 days)
- CE&R Enhance URM and other high risk group enrollment in trials
- CCTSI COVID-19 Related Research (C2R2) Pilot Grant Program < 2 weeks
- CU-CSU Summits x2 focusing on COVID research
- COVIDome and Biobank
- Remote learning for Educational programs
- National COVID-19 Cohort Collaborative (N3C) involvement

CCTSI Response to COVID-19


- CHCO CTRC facilitated largest enrollment center (10% of all enrollees 80 sites, 2,268) for Pfizer/BNT COVID vaccine trial in 5-11 yr-old children (NEJM Nov 9, 2021)
- Adult CTRC and CReST facilitated numerous adult therapeutic trials
- CEAL site for Colorado (Nease)
 NHLBI
- mAb Monoclonal Ab Real World Evidence study (Admin Supplement Ginde-led Team) NCATS
- RECOVER (Long COVID) Clinical Cohort Site (Mtn. States Consortium -Erlandson), and Real-World Evidence Data Center- N3C (Haendel, Bennett) NHLBI



Diversity, Equity, Inclusion, Social Justice

- Formed CCTSI DEI/SJ Committee
 - DEI and Land Acknowledgement Statements posted on our home page
 - Examining our programs and hiring practices for systematic racism
 - Surveyed our staff for DEI training readiness
 - Mandatory DEI training for all CCTSI staff
 - Considering mechanism to train all Clinical Research Coordinators on campus (n=600) in DEI/SJ
 - Revising Selection Processes for WFD programs
 - Coordinate with Regina Richards PhD, VC DEI &CE, and Dominic Martinez, Asst VC Diversity, Equity, Inclusion & Community Engagement – Pathway (Pipeline) Programs and many others
 - Posted "COVID-19 Impact on Latinos" Fact Sheet on website







Professional Workforce Development

 Summer Undergraduate Minority Mentoring in Translational Science (SUMMiT) (n=14) – Pathway Program



- 2. TL1 (T32) Pre-doctoral PhD training program
- 3. Clinical Sciences Graduate Program (PhD, Masters)
- 4. KL2 (K12) Research Scholar program up to 3 yrs. of support
- 5. Clinical Research Training and Education (CRSC)
- 6. Support for Clinical Faculty Scholars Program



Professional Workforce Development

- 7. Leadership in Innovative Team Science (LITeS)
- 8. Colorado Mentor Training Program
- 9. K-to-R Transition Grant Review
- 10. Pre-K Award Assistance and Grant Review
- 11. Research Studios
- 12. Innovation Corps (I-Corps)
- 13. *NEW* Teaming for Early Career Researchers
- 14. *NEW* Communicating Your Science to the Public

COlorado Clinical and Translational Sciences Institute (CCTSI)



Communicating Your Science to the Public

New workshop series - Communicating Your Science to the Public. We believe that one of the best ways to increase trust in science is to empower researchers with the skills to communicate their work. Offered Quarterly for up to 30 per session. Started in Spring 2021.

- Workshop #1: Effectively communicating your message to the public
- Workshop #2: Sharing your message effectively and giving/receiving feedback
- Workshop #3: Expanding your media horizons



Taught by Comilla Sasson, MD, PhD



Colorado Clinical and Translational Sciences Institute (CCTSI)

Clinical Translational Research Centers (CTRCs)

- UCH, CHCO, NJH & CU B
 - Inpatient and outpatient facilities and mobile teams



- Nursing, Nutrition, metabolic kitchen, whole room calorimeter, body composition, exercise physiology, vascular ultrasonography and ECHO, Core laboratories & specimen processing
- *Microgrants* to Jr. Investigators (\$10,000/yr. x 3)
- 200 PI's > 500 CTRC Protocols each year (10,000 15,000 visits/yr)
- CReST: Clinical Research Support Team coordinators and regulatory (FFS)
 - CReST moved into VCR Office




Administrative Supplements

KL2 – INCLUDE Supplemental Award

- INvestigation of Co-Occurring Conditions across the Lifespan to Understand Down SyndromE
- Marisa Stahl, MD, MSCS pediatric gastroenterology Asst Professor
- Aim 1: Identify multi-omics signatures of celiac disease in DS.
- Aim 2: Define if signatures of celiac disease in DS are conserved in celiac disease in typical children.
- Aim 3: Define the impact of risk alleles on celiac disease in DS
- 2020-2023





Diversity KL2 Supplement (UL1)

KL2 – Diversity Supplemental Award


- Health disparities and inequities in care delivery for peripheral arterial disease (PAD) among Black and Hispanic Americans
- Demetria M. McNeal PhD, MBA-Asst Professor, Internal Medicine
- Aim 1: Determine knowledge, role in management, perceptions, etc. among clinicians related to treatment of PAD in Blacks and Latinx
- Aim 2: Determine knowledge, access to care and self-management behaviors among patients with PAD
- Aim 3: Determine how these aspects have been affected by COVID-19.
- 2021-2023



Colorado Clinical and Translational Sciences Institute (CCTSI) UNIVERSITY OF COLORADO DENVER | ANSCHUTZ MEDICAL CAMPUS



AMC INNOVATION ECOSYSTEM



Trial Innovation Network Hub Liaison Team

- **Director**: Adit Ginde, MD, MPH
- Medical Directors: Tom Campbell, MD (UCH) and Jesse Davidson, MD (CHCO)
- Project Manager: Ben schalier
- Contracting Lead: Amanda Peng
- Central IRB Lead: Christy Williamson
- Recruitment (Participants) Lead: Barbara Hammack
- Navigator: Cynthia Sneddon

Local Website, workflow, educational materials, etc.



National CTSA Consortium Involvement

- Ronald Sokol, MD National CTSA Steering Committee 2020-2023
- CD2H Melissa Haendel, PhD
- N3C Melissa Haendel, PhD and Tell Bennett, MD, MS
- Members of all Enterprise Committees
- U01 CCIA grant Telehealth Research in Pediatrics (SPROUT)
- Northern LITeS (University of Minnesota CTSA)
- I-Corps@CTSA national expansion Cathy Bodine, PhD (UAB U01)
- COHA Sue VanDewoude, DVM, Dean Vet School CSU
- Several CCIA U01 grants undergoing review
- mAb, CO-CEAL, RECOVER



CCTSI 4.0 – New Grant Submissions

- FOA PAR 21-293 released July 30, 2021: 7 grant options to replace U54
- UM1 for 7 years
 K12, Pre-Doc and Post-Doc T32, RC2 (up to two) and R25 all for 5 years
- UM1 Budget determined by NIH funding tier C, \$5 million direct costs (\$800K below our UL1)
- New FOA emphasis on translational science and not research, new Clinical & Translational Science Research Program (Element E), 7 attachments
- Submitted 6 grants on May 13, 2022 (budget period May 1, 2023-2030)
- Huge effort did not reduce our "administrative burden"
 - We submitted a UM1, K12, pre-Doc TL32, post-Doc TL32, and two RC2 applications
 - Would not advise any CTSAs attempt to submit more than 4 of these concurrently



CCTSI Grant Submission Outcomes

- Scores: UM1 29, K12 20, PreDoc T32 19, PostDoc T32 30, RC2 both not discussed
- UM1 on the borderline for funding (must have both UM1 and K12 funded in order to receive funding for any of the grants)
- Received Summary Statement ~ Dec. 1, 2022 (you received it)
- Advised by NIH to resubmit UM1 A1 grant for January 13, 2023 deadline (<u>yes, tomorrow</u>) and address the Weaknesses cited (one page Introduction allowed)
- Over December we assembled an A1 application & it is submitted. To be reviewed in May, earliest start date, Dec. 1, 2023
- Awaiting decision about funding for May 2022 submission



Contingency Plans

- Using CCSTI Reserves and Commitments can keep all programs functioning for 9-12 months
- Will not accept new K12 or T32 scholars but complete those in program. Scale down Pilot Grant program as needed.
- Share costs (50:50) with Partnering Institutions
- Possibility to get "Cost Extension" funding from NCATS (50% direct costs for up to one year) but no guarantee
- Rewrite RC2 (? Post-Doc T32) grants for upcoming submission dates



UM1 Weakness Cited by Reviewers

- Assimilation of components into a unified form, components should complement each other, collaborations among partners
- Enhance Communication Plan
- Denver-Boulder centric coordination of other institutions with CCTSI; statewide reach not clear
- Novel ways to enhance diversity of workforce
- Specific initiatives for URM faculty, trainees and staff
- Plans to promote health equity
- More details on Metrics and CQI plans
- Feedback from Community Stakeholders and Workforce
- Describe future plans in more details
- Concern about EHR consenting (Element E) for those without EHR access or expertise



Our A1 Application Response

- Thorough A1 grant revision performed (including new diagrams/charts)
- Improved and more detailed description of interactions and coordination of CCTSI and with/among Partnering Institutions
- Effort to add and emphasize pipeline programs for URMs, recruitment and mentoring of URMs, approach to supporting research for Health Disparities and Inequities
- Expanded Metrics for each section
- More detailed Communication Plans
- Feedback from Community and Workforce Stakeholders addressed
- Addressed EHR recruitment plans for rural, minority groups, non-EHR user patients and risk for introducing bias



CCTSI 4.0 Overall Strategic Goals

Goal 1: Advance CTS by developing, demonstrating, and disseminating innovative programs to improve the efficiency and impact of translation across the entire T0.5 to T4 spectrum.

Goal 2: Promote collaboration, team and data science, and partnerships to accelerate CTR locally, regionally and nationally.

Goal 3: Partner locally, regionally and nationally with institutions, stakeholders and communities to develop innovative research programs that will address health inequities and disparities.




CCTSI 4.0 Overall Strategic Goals

Goal 4: Further develop operational efficiencies to increase the quality, safety, efficiency, effectiveness and informativeness of clinical research.


Goal 5: Promote a safe and nimble research environment that can rapidly respond to urgent public health needs.

Goal 6: Develop and disseminate CTS training programs that educate and sustain a resilient, diverse team of clinical research professionals.





Working Relationships Between CCTSI Hub and Partnering Institutions



Ð

Elements and Modules

A. Overall

- B. Strategic Management
- C. Training and Outreach

C1. Workforce Development

C2. Community and Stakeholder Engagement Research

D. Clinical and Translational Science Resources and Pilots

- D1. Resources and Services
- D2. CTS Pilot Program
- D3. Health Informatics
- E. Clinical and Translational Science Research Program

Seven Attachments/tables/charts



DISCUSSION